Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Callan Capital LLC

Callan Capital LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 281.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,191 shares of the pharmaceutical company’s stock after purchasing an additional 3,091 shares during the period. Callan Capital LLC’s holdings in Vertex Pharmaceuticals were worth $1,705,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Venturi Wealth Management LLC boosted its stake in Vertex Pharmaceuticals by 1.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after buying an additional 24 shares during the period. Nicholas Hoffman & Company LLC. boosted its stake in shares of Vertex Pharmaceuticals by 3.9% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock valued at $259,000 after purchasing an additional 24 shares during the period. Arthur M. Cohen & Associates LLC boosted its stake in shares of Vertex Pharmaceuticals by 3.2% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after purchasing an additional 25 shares during the period. Baystate Wealth Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the period. Finally, Arjuna Capital boosted its stake in shares of Vertex Pharmaceuticals by 0.7% in the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after purchasing an additional 29 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on VRTX. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. Royal Bank of Canada lifted their price target on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 6th. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target for the company in a research note on Thursday, April 11th. Finally, Truist Financial lifted their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $429.45.

Insider Activity

In other news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 in the last 90 days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $397.48 on Friday. The firm has a market cap of $102.73 billion, a price-to-earnings ratio of 28.62, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average is $411.60 and its two-hundred day moving average is $398.67. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the firm earned $3.33 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.